Overview

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

Status:
Not yet recruiting

Trial end date:
2023-10-31

Target enrollment:

Participant gender:

Summary

This is an open-label, single center, pilot study to assess the feasibility of baseline 89Zr-trastuzumab PET/CT to predict response to treatment with monotherapy MT-5111

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Molecular Templates, Inc.

Treatments:

Trastuzumab